Lakshmi Kallur, MD
Pulmonary Disease · Hickory, NCNPI 1073992343
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.2% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $6,555, more than ten times the $140 reported in 2019.
Across 100 payments — averaging $96.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$433
- GSK$164
- Genentech USA, Inc.$140
- Amgen$132
- Grifols USA, LLC$125
- plus $919 from 20 others
What the payments were for
- Travel & lodging$2,21023%
- Food & beverage$1,96320%
- Education$5,50057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,760 |
| AstraZeneca | 23 | $433 |
| GSK | 9 | $164 |
| Genentech USA, Inc. | 1 | $140 |
| Amgen | 6 | $132 |
| Grifols USA, LLC | 6 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $118 |
| Mylan Specialty L.p. | 6 | $112 |
| United Therapeutics Corporation | 4 | $102 |
| Boehringer Ingelheim | 4 | $92 |
| Baxter Healthcare | 4 | $80 |
| Johnson & Johnson | 1 | $57 |
| ANI Pharmaceuticals, Inc. | 3 | $48 |
| Insmed, Inc. | 2 | $45 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Philips North America LLC | 1 | $29 |
| Merck | 2 | $29 |
| Sanofi | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $22 |
| Electromed, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $17 |
| Biomerieux Inc | 1 | $16 |
| Pulmonx Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,674
How this compares
$9,673 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 23 | $537,598 |
| OfevNintedanib Esylate | 28 | $345,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $180,706 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $50,719 |
| Spiriva RespimatTiotropium Bromide | 44 | $35,431 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $18,371 |
| Tadalafil | 18 | $15,872 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,792 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $14,616 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 319 | $7,170 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,331 |
| Roflumilast | 35 | $3,344 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,873 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,784 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $92 | $395,54997 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $164 | $214,870248 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $433 | $55,05179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Hickory
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.